Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma

Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma: /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect...